| Original language | English |
|---|---|
| Pages (from-to) | 455-456 |
| Number of pages | 2 |
| Journal | JAMA Internal Medicine |
| Volume | 182 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2022 |
| Externally published | Yes |
Bibliographical note
Funding Information:payments to her institution for speaking engagements from 3M, Becton Dickinson, Cardinal Health, and Eloquest, outside the submitted work. Dr Paterson reported funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; board membership for Janssen, Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; grants from Pfizer, Shionogi, and Merck; speaking fees from Pfizer, all outside the submitted work. No other disclosures were reported.
Funding
payments to her institution for speaking engagements from 3M, Becton Dickinson, Cardinal Health, and Eloquest, outside the submitted work. Dr Paterson reported funding from AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; board membership for Janssen, Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate; grants from Pfizer, Shionogi, and Merck; speaking fees from Pfizer, all outside the submitted work. No other disclosures were reported.
| Funders | Funder number |
|---|---|
| Cubist | |
| Leo Pharmaceuticals | |
| Pfizer | |
| AstraZeneca | |
| Bayer | |
| GlaxoSmithKline | |
| Merck | |
| Shionogi |